Psychometric Properties of the Turkish Versions of the Cannabis Use Problems Identification Test (CUPIT) and the Adult Cannabis Problems Questionnaire (CPQ)


Evren C., Cengel H. Y., Bozkurt M., Evren B., Umut G., Agachanli R.

JOURNAL OF PSYCHOACTIVE DRUGS, vol.49, no.1, pp.83-89, 2017 (SSCI) identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1080/02791072.2016.1277047
  • Journal Name: JOURNAL OF PSYCHOACTIVE DRUGS
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus
  • Page Numbers: pp.83-89
  • Keywords: Cannabis, CPQ, CUPIT, psychometric properties, synthetic cannabinoid, INVENTORY MSI-X, USE DISORDER, RELIABILITY, ALCOHOL, TRENDS, CONCURRENT, VALIDITY
  • Istanbul University Affiliated: Yes

Abstract

Cannabis and synthetic cannabinoids are widely used illicit substances in Turkey. The Cannabis Use Problems Identification Test (CUPIT) is a brief self-report screening instrument for detection of problematic cannabis use, whereas the Cannabis Problems Questionnaire (CPQ) is a measure for cannabis treatment outcome. The aim of this study was to evaluate the psychometric properties of the CUPIT and CPQ among Turkish male outpatients with cannabis (n = 52) and synthetic cannabinoid (n = 45) use disorder. Participants were evaluated with the CUPIT, the CPQ, and the Cannabis Withdrawal Scale (CWS). Principal Component Analysis (PCA) supported two-factor construct validity for CUPIT. Cronbach's alpha was 0.84 for CUPIT-A factor, 0.83 for CUPIT-B factor, and 0.89 for CUPIT, when considered as a unidimensional scale. Cronbach's alpha was 0.82 for CPQ-A factor, 0.73 for CPQ-B factor, 0.30 for CPQ-C, and 0.87 for CPQ, when considered as a unidimensional scale. The CUPIT and the CPQ were moderately correlated with the CWS (r = 0.63 and r = 0.74, respectively), whereas the CUPIT and the CPQ were strongly correlated with each other (r = 0.76). The Turkish version of the CUPIT and the CPQ can effectively identify substance use problems and treatment outcome, respectively, among outpatients with cannabis or synthetic cannabinoid use disorder.